Results showed median pTau217 levels of 0.65 in the CN group, 1.34 in EMCI, and 2.19 in LMCI (p = 0.017); median pTau217_ratio values were 2.21 (CN), 2.37 (EMCI), and 3.94 (LMCI) (p = 0.013), indicating a continuous increase in plasma tau protein levels with cognitive decline, consistent with other studies and disease progression. The gene discussed is MAPT; the disease is Mental deterioration.